Chi KN - Search Results

1

CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update.

Saad F, Hotte S, Catton C, Drachenberg D, Finelli A, Fleshner N, Gleave M, Kapoor A, Kassouf W, Loblaw A, North S, Usmani N, Chi KN. Saad F, et al. Among authors: chi kn. Can Urol Assoc J. 2013 Jul-Aug;7(7-8):231-7. doi: 10.5489/cuaj.1542. Can Urol Assoc J. 2013. PMID: 24032056 Free PMC article. No abstract available.

2

Antisense approaches in prostate cancer.

Chi KN, Gleave ME. Chi KN, et al. Expert Opin Biol Ther. 2004 Jun;4(6):927-36. doi: 10.1517/14712598.4.6.927. Expert Opin Biol Ther. 2004. PMID: 15174974 Review.

3

Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.

Eigl BJ, Eggener SE, Baybik J, Ettinger S, Chi KN, Nelson C, Wang Z, Gleave ME. Eigl BJ, et al. Among authors: chi kn. Clin Cancer Res. 2005 Jul 1;11(13):4905-11. doi: 10.1158/1078-0432.CCR-04-2140. Clin Cancer Res. 2005. PMID: 16000589 Free article.

4

Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancers.

Gleave M, Chi KN. Gleave M, et al. Among authors: chi kn. Ann N Y Acad Sci. 2005 Nov;1058:1-15. doi: 10.1196/annals.1359.001. Ann N Y Acad Sci. 2005. PMID: 16394121 Review.

5

A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer.

Chi KN, Siu LL, Hirte H, Hotte SJ, Knox J, Kollmansberger C, Gleave M, Guns E, Powers J, Walsh W, Tu D, Eisenhauer E. Chi KN, et al. Clin Cancer Res. 2008 Feb 1;14(3):833-9. doi: 10.1158/1078-0432.CCR-07-1310. Clin Cancer Res. 2008. PMID: 18245546 Clinical Trial.

6

Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer.

Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME. Chi KN, et al. J Urol. 2008 Aug;180(2):565-70; discussion 570. doi: 10.1016/j.juro.2008.04.012. Epub 2008 Jun 12. J Urol. 2008. PMID: 18554663 Clinical Trial.

7

Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer.

Chi KN, Zoubeidi A, Gleave ME. Chi KN, et al. Expert Opin Investig Drugs. 2008 Dec;17(12):1955-62. doi: 10.1517/13543780802528609. Expert Opin Investig Drugs. 2008. PMID: 19012510 Review.

8

Castration-resistant prostate cancer: from new pathophysiology to new treatment targets.

Chi KN, Bjartell A, Dearnaley D, Saad F, Schröder FH, Sternberg C, Tombal B, Visakorpi T. Chi KN, et al. Eur Urol. 2009 Oct;56(4):594-605. doi: 10.1016/j.eururo.2009.06.027. Epub 2009 Jun 24. Eur Urol. 2009. PMID: 19560857 Review.

9

Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.

Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, Saad F, North S, Powers J, Gleave ME, Eisenhauer EA. Chi KN, et al. J Clin Oncol. 2010 Sep 20;28(27):4247-54. doi: 10.1200/JCO.2009.26.8771. Epub 2010 Aug 23. J Clin Oncol. 2010. PMID: 20733135 Clinical Trial.

10

A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer.

Beardsley EK, Hotte SJ, North S, Ellard SL, Winquist E, Kollmannsberger C, Mukherjee SD, Chi KN. Beardsley EK, et al. Among authors: chi kn. Invest New Drugs. 2012 Aug;30(4):1652-9. doi: 10.1007/s10637-011-9722-5. Epub 2011 Jul 23. Invest New Drugs. 2012. PMID: 21785998 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

281 results

Search Page

Filters